GRPH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 kov. 2024 @ 22:00):

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States...

Stats
Šios dienos apimtis	299 406
Vidutinė apimtis	40 955.00
Rinkos kapitalizacija	185.19M
EPS	$-0.400 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.0600 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-28	Drapkin Kimberlee C	Buy	40 000	Stock Option (right to buy)
2023-07-28	Drapkin Kimberlee C	Buy	0
2023-07-19	Viney Joanne L.	Buy	20 000	Stock Option (right to buy)
2023-07-19	Porteus Matthew	Buy	20 000	Stock Option (right to buy)
2023-07-19	Karsen Perry A	Buy	20 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 36 276 632 \| Sell: 68 481 989

Tūris Koreliacija

Ilgas: 0.15 (neutral)

Trumpas: 0.77 (moderate)

Signal:(51.506) Neutral

Graphite Bio, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SGLB	0.895
MTEX	0.893
ZENV	0.882
GRIN	0.88
PIII	0.874
RIVN	0.872
LCAP	0.868
SOPA	0.868
LAWS	0.865
OP	0.865

10 Labiausiai neigiamai susiję koreliacijos
DYNT	-0.95
FTFT	-0.949
DGLY	-0.935
ATNX	-0.924
CRNC	-0.921
CFRX	-0.918
FGEN	-0.914
IPHA	-0.913
CSWI	-0.912
ECOR	-0.912

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Graphite Bio, Inc. Koreliacija - Valiuta/Žaliavos

0.38
( neutral )

0.58
( weak )

0.00
( neutral )

0.54
( weak )

0.16
( neutral )

Graphite Bio, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2023
Pajamos:	$0
Bruto pelnas:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2022
Pajamos:	$0
Bruto pelnas:	$-8.35M (0.00 %)
EPS:	$-1.760

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.45

Financial Reports:

No articles found.

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.